Kazia Therapeutics Share Price and Company Fundamentals
Last traded: Today at 5:59 AM
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
|Primary activities||Kazia Therapeutics partners with the world¿¿¿s leading researchers and drug developers to bring forward a diversified portfolio of new cancer therapies.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 Australia|
|Phone / Fax||1300 787 272 /|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Kazia Therapeutics does not pay dividends.
As of May 2021, following are the company executives and directors listed on Kazia Therapeutics.
|Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (||CEO, MD & Exec. Director||47||738.46k|
|Ms. Gabrielle Heaton||Director of Fin. & Admin.||239.96k|
|Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons)||Company Sec.||60||142.88k|
|Kym Robins||Director of Marketing & Communications|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Kazia Therapeutics is 151.9M and its enterprise value is 140.23M. The enterprise value to revenue ratio of KZA is 385.80.
The KZA's stocks Beta value is 2.75 making it 175% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Kazia Therapeutics (KZA)
Kazia Therapeutics (ASX:KZA) Frequently Asked Questions
1. What is Kazia Therapeutics's Stock Symbol?
Kazia Therapeutics trades on ASX under the ticker symbol "KZA".
2. What is Kazia Therapeutics's stock price today?
One share of KZA stock can currently be purchased for approximately $1.2.
3. How can I contact Kazia Therapeutics?
Kazia Therapeutics's mailing address is Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 Australia. The company can be reached via phone at 1300 787 272.
4. What is Kazia Therapeutics's official website?
The official website of Kazia Therapeutics is http://www.kaziatherapeutics.com.
5. Which share registry manages Kazia Therapeutics's stock?
Kazia Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.